| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 42 | 2024 | 1858 | 3.150 |
Why?
|
| Anti-HIV Agents | 13 | 2024 | 304 | 2.040 |
Why?
|
| Infectious Disease Transmission, Vertical | 14 | 2022 | 237 | 1.560 |
Why?
|
| HIV-1 | 8 | 2022 | 463 | 0.970 |
Why?
|
| Drug Resistance, Viral | 3 | 2022 | 44 | 0.940 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 1 | 2022 | 60 | 0.800 |
Why?
|
| Pregnancy Complications, Infectious | 9 | 2022 | 440 | 0.750 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2022 | 204 | 0.700 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2022 | 334 | 0.650 |
Why?
|
| CD8-Positive T-Lymphocytes | 6 | 2017 | 398 | 0.620 |
Why?
|
| Anti-Retroviral Agents | 5 | 2022 | 135 | 0.560 |
Why?
|
| Homeless Youth | 3 | 2024 | 11 | 0.530 |
Why?
|
| Diketopiperazines | 1 | 2024 | 3 | 0.470 |
Why?
|
| Viral Load | 7 | 2019 | 380 | 0.430 |
Why?
|
| Sexual and Gender Minorities | 2 | 2024 | 59 | 0.390 |
Why?
|
| Granulomatous Disease, Chronic | 5 | 2011 | 65 | 0.380 |
Why?
|
| Adolescent | 28 | 2024 | 18940 | 0.340 |
Why?
|
| HIV Seropositivity | 2 | 2010 | 116 | 0.340 |
Why?
|
| Medication Adherence | 3 | 2019 | 384 | 0.330 |
Why?
|
| Risk Reduction Behavior | 1 | 2010 | 132 | 0.330 |
Why?
|
| Child | 28 | 2024 | 24063 | 0.300 |
Why?
|
| Acquired Immunodeficiency Syndrome | 5 | 2004 | 233 | 0.270 |
Why?
|
| Pregnancy | 14 | 2022 | 7092 | 0.260 |
Why?
|
| Pre-Exposure Prophylaxis | 2 | 2024 | 32 | 0.260 |
Why?
|
| Sexual Behavior | 4 | 2024 | 234 | 0.260 |
Why?
|
| Female | 42 | 2024 | 64882 | 0.260 |
Why?
|
| Humans | 54 | 2024 | 122293 | 0.250 |
Why?
|
| Health Personnel | 1 | 2010 | 500 | 0.250 |
Why?
|
| Sexually Transmitted Diseases | 2 | 2024 | 93 | 0.250 |
Why?
|
| Case Management | 1 | 2024 | 22 | 0.240 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2005 | 34 | 0.240 |
Why?
|
| Infant, Newborn | 14 | 2022 | 8096 | 0.240 |
Why?
|
| Severe Combined Immunodeficiency | 3 | 2010 | 106 | 0.240 |
Why?
|
| Antigens, CD | 2 | 2008 | 419 | 0.230 |
Why?
|
| Male | 33 | 2024 | 59520 | 0.230 |
Why?
|
| AIDS-Related Opportunistic Infections | 3 | 2013 | 139 | 0.220 |
Why?
|
| Antibodies, Viral | 2 | 2022 | 1131 | 0.220 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2017 | 469 | 0.210 |
Why?
|
| CD4 Lymphocyte Count | 5 | 2022 | 230 | 0.210 |
Why?
|
| Immunologic Tests | 1 | 2002 | 23 | 0.210 |
Why?
|
| Vaccines, Attenuated | 1 | 2022 | 171 | 0.200 |
Why?
|
| Papillomavirus Infections | 2 | 2021 | 271 | 0.200 |
Why?
|
| Young Adult | 11 | 2024 | 8760 | 0.200 |
Why?
|
| Cough | 1 | 2022 | 87 | 0.200 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2022 | 145 | 0.200 |
Why?
|
| HIV Long-Term Survivors | 1 | 2001 | 3 | 0.190 |
Why?
|
| United States | 11 | 2024 | 10487 | 0.190 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 28 | 0.190 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2013 | 265 | 0.190 |
Why?
|
| Anus Neoplasms | 1 | 2021 | 38 | 0.190 |
Why?
|
| Adult | 19 | 2024 | 28732 | 0.190 |
Why?
|
| Infant | 19 | 2016 | 12302 | 0.180 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2002 | 201 | 0.180 |
Why?
|
| Papillomavirus Vaccines | 1 | 2021 | 92 | 0.180 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2001 | 194 | 0.170 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2017 | 226 | 0.170 |
Why?
|
| Prevalence | 7 | 2024 | 2371 | 0.170 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 454 | 0.160 |
Why?
|
| Mothers | 1 | 2022 | 346 | 0.160 |
Why?
|
| Child, Preschool | 16 | 2022 | 13777 | 0.160 |
Why?
|
| Chemoprevention | 2 | 2015 | 60 | 0.160 |
Why?
|
| Treatment Failure | 1 | 2019 | 336 | 0.150 |
Why?
|
| Cohort Studies | 10 | 2022 | 4643 | 0.150 |
Why?
|
| Depressive Disorder, Major | 1 | 2022 | 396 | 0.140 |
Why?
|
| Disease Transmission, Infectious | 1 | 2018 | 85 | 0.140 |
Why?
|
| Killer Cells, Natural | 1 | 2019 | 325 | 0.140 |
Why?
|
| Methylprednisolone | 1 | 1996 | 90 | 0.130 |
Why?
|
| Esophageal Diseases | 1 | 1996 | 35 | 0.130 |
Why?
|
| Eosinophils | 1 | 2017 | 120 | 0.130 |
Why?
|
| Minors | 1 | 2015 | 5 | 0.130 |
Why?
|
| Chickenpox Vaccine | 1 | 2015 | 13 | 0.130 |
Why?
|
| Prednisone | 1 | 1996 | 273 | 0.130 |
Why?
|
| Chickenpox | 1 | 2015 | 20 | 0.130 |
Why?
|
| Genotype | 1 | 2022 | 2525 | 0.130 |
Why?
|
| Parental Consent | 1 | 2015 | 25 | 0.130 |
Why?
|
| Asthma | 2 | 2017 | 743 | 0.130 |
Why?
|
| Research Subjects | 1 | 2015 | 55 | 0.120 |
Why?
|
| Rilpivirine | 1 | 2024 | 1 | 0.120 |
Why?
|
| Glucocorticoids | 1 | 1996 | 379 | 0.110 |
Why?
|
| Papillomaviridae | 2 | 2021 | 135 | 0.110 |
Why?
|
| Africa, Southern | 1 | 2023 | 7 | 0.110 |
Why?
|
| Health Policy | 1 | 2015 | 208 | 0.110 |
Why?
|
| Global Health | 1 | 2018 | 555 | 0.110 |
Why?
|
| Pyridones | 1 | 2024 | 111 | 0.110 |
Why?
|
| South Africa | 1 | 2023 | 98 | 0.110 |
Why?
|
| Asia | 1 | 2023 | 105 | 0.110 |
Why?
|
| Dangerous Behavior | 1 | 2012 | 11 | 0.110 |
Why?
|
| Homosexuality, Male | 2 | 2024 | 61 | 0.100 |
Why?
|
| Food Supply | 1 | 2013 | 97 | 0.100 |
Why?
|
| Europe | 1 | 2023 | 369 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2011 | 1192 | 0.100 |
Why?
|
| Incidence | 6 | 2017 | 3018 | 0.100 |
Why?
|
| Child Behavior Disorders | 1 | 2012 | 68 | 0.100 |
Why?
|
| Unrelated Donors | 1 | 2011 | 81 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 1084 | 0.090 |
Why?
|
| HIV | 2 | 2022 | 179 | 0.090 |
Why?
|
| Malawi | 3 | 2017 | 389 | 0.090 |
Why?
|
| RNA, Viral | 3 | 2010 | 540 | 0.080 |
Why?
|
| Professional-Patient Relations | 1 | 2010 | 83 | 0.080 |
Why?
|
| Osteomyelitis | 2 | 2007 | 201 | 0.080 |
Why?
|
| Rotavirus Vaccines | 1 | 2010 | 71 | 0.080 |
Why?
|
| Postpartum Period | 2 | 2021 | 206 | 0.080 |
Why?
|
| Sleep | 1 | 2012 | 336 | 0.080 |
Why?
|
| Truth Disclosure | 1 | 2010 | 103 | 0.080 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2008 | 39 | 0.080 |
Why?
|
| Longitudinal Studies | 3 | 2019 | 1283 | 0.080 |
Why?
|
| Interviews as Topic | 1 | 2010 | 367 | 0.080 |
Why?
|
| Disease Progression | 4 | 2006 | 1990 | 0.080 |
Why?
|
| Lymphocyte Depletion | 1 | 2008 | 122 | 0.080 |
Why?
|
| Tissue Donors | 1 | 2011 | 498 | 0.080 |
Why?
|
| Failure to Thrive | 2 | 2010 | 89 | 0.080 |
Why?
|
| Herpesvirus 2, Human | 1 | 2008 | 13 | 0.080 |
Why?
|
| Central Nervous System Diseases | 1 | 2009 | 105 | 0.080 |
Why?
|
| Herpes Genitalis | 1 | 2008 | 11 | 0.080 |
Why?
|
| Prospective Studies | 5 | 2021 | 5963 | 0.070 |
Why?
|
| Cognition Disorders | 1 | 2012 | 551 | 0.070 |
Why?
|
| Transplantation Conditioning | 1 | 2009 | 322 | 0.070 |
Why?
|
| Basidiomycota | 1 | 2007 | 11 | 0.070 |
Why?
|
| Vaccination | 2 | 2024 | 927 | 0.070 |
Why?
|
| Central Nervous System | 1 | 2009 | 253 | 0.070 |
Why?
|
| Rotavirus Infections | 1 | 2010 | 353 | 0.070 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2007 | 91 | 0.070 |
Why?
|
| Rotavirus | 1 | 2010 | 496 | 0.070 |
Why?
|
| Cytokines | 1 | 2012 | 1272 | 0.070 |
Why?
|
| Mycoses | 1 | 2007 | 116 | 0.070 |
Why?
|
| Cross-Sectional Studies | 4 | 2017 | 3301 | 0.070 |
Why?
|
| Bone Marrow Transplantation | 1 | 2008 | 581 | 0.060 |
Why?
|
| Condoms | 1 | 2024 | 48 | 0.060 |
Why?
|
| Growth | 1 | 2005 | 107 | 0.060 |
Why?
|
| Executive Function | 2 | 2017 | 101 | 0.060 |
Why?
|
| Immunophenotyping | 1 | 2005 | 333 | 0.060 |
Why?
|
| Morbidity | 1 | 2005 | 239 | 0.060 |
Why?
|
| Community-Based Participatory Research | 1 | 2024 | 50 | 0.060 |
Why?
|
| ROC Curve | 1 | 2005 | 552 | 0.050 |
Why?
|
| Women's Health | 1 | 2004 | 129 | 0.050 |
Why?
|
| Lymphocyte Activation | 1 | 2005 | 680 | 0.050 |
Why?
|
| Waiting Lists | 1 | 2024 | 220 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 1022 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2005 | 810 | 0.050 |
Why?
|
| Medication Therapy Management | 1 | 2022 | 25 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2004 | 217 | 0.050 |
Why?
|
| NAD+ Nucleosidase | 1 | 2001 | 2 | 0.050 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 2001 | 4 | 0.050 |
Why?
|
| CD57 Antigens | 1 | 2001 | 5 | 0.050 |
Why?
|
| Cobicistat | 1 | 2021 | 1 | 0.050 |
Why?
|
| Darunavir | 1 | 2021 | 3 | 0.050 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2001 | 17 | 0.050 |
Why?
|
| Graft vs Host Disease | 3 | 2011 | 542 | 0.050 |
Why?
|
| HLA-DR Antigens | 1 | 2001 | 76 | 0.050 |
Why?
|
| Antigens, Differentiation | 1 | 2001 | 63 | 0.050 |
Why?
|
| Anal Canal | 1 | 2021 | 80 | 0.050 |
Why?
|
| Income | 1 | 2022 | 133 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2005 | 1592 | 0.050 |
Why?
|
| CD28 Antigens | 1 | 2001 | 78 | 0.050 |
Why?
|
| Interleukin-10 | 1 | 2002 | 170 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2005 | 1147 | 0.050 |
Why?
|
| Immune Tolerance | 1 | 2001 | 145 | 0.040 |
Why?
|
| Logistic Models | 2 | 2017 | 1772 | 0.040 |
Why?
|
| Patient Selection | 1 | 2024 | 685 | 0.040 |
Why?
|
| Growth Disorders | 1 | 2022 | 208 | 0.040 |
Why?
|
| Substance-Related Disorders | 1 | 2005 | 456 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 1678 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 2010 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2002 | 508 | 0.040 |
Why?
|
| Poisson Distribution | 2 | 2013 | 48 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2022 | 12044 | 0.040 |
Why?
|
| Immunoglobulin E | 2 | 2017 | 152 | 0.040 |
Why?
|
| CD4-CD8 Ratio | 1 | 2019 | 13 | 0.040 |
Why?
|
| Infant, Premature | 1 | 2005 | 799 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2001 | 414 | 0.040 |
Why?
|
| Epidemiological Monitoring | 1 | 2018 | 59 | 0.040 |
Why?
|
| Stereotyping | 1 | 2017 | 18 | 0.040 |
Why?
|
| International Cooperation | 1 | 2018 | 160 | 0.040 |
Why?
|
| Internationality | 1 | 2018 | 128 | 0.040 |
Why?
|
| Placenta | 1 | 2021 | 487 | 0.040 |
Why?
|
| DNA, Viral | 2 | 2010 | 492 | 0.030 |
Why?
|
| Mycobacterium avium Complex | 1 | 1996 | 22 | 0.030 |
Why?
|
| Time Factors | 3 | 2017 | 6182 | 0.030 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 1996 | 24 | 0.030 |
Why?
|
| Hospitalization | 1 | 2005 | 1727 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2017 | 194 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1996 | 254 | 0.030 |
Why?
|
| Disclosure | 1 | 2017 | 153 | 0.030 |
Why?
|
| Risk Factors | 4 | 2013 | 9902 | 0.030 |
Why?
|
| State Government | 1 | 2015 | 30 | 0.030 |
Why?
|
| Prognosis | 1 | 2005 | 4488 | 0.030 |
Why?
|
| Maternal Exposure | 1 | 2017 | 148 | 0.030 |
Why?
|
| Linear Models | 2 | 2013 | 657 | 0.030 |
Why?
|
| Seroepidemiologic Studies | 1 | 2015 | 114 | 0.030 |
Why?
|
| Algorithms | 1 | 2022 | 1575 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2017 | 228 | 0.030 |
Why?
|
| Colitis | 1 | 1996 | 153 | 0.030 |
Why?
|
| Aspergillus fumigatus | 1 | 1994 | 41 | 0.030 |
Why?
|
| Aspergillosis | 1 | 1994 | 42 | 0.030 |
Why?
|
| Administration, Oral | 1 | 1996 | 668 | 0.030 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1996 | 220 | 0.030 |
Why?
|
| Spinal Diseases | 1 | 1994 | 46 | 0.030 |
Why?
|
| Self Report | 1 | 2017 | 496 | 0.030 |
Why?
|
| Amphotericin B | 1 | 1994 | 90 | 0.030 |
Why?
|
| Depression | 1 | 2022 | 1214 | 0.030 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2013 | 18 | 0.030 |
Why?
|
| Premedication | 1 | 2013 | 44 | 0.030 |
Why?
|
| Diet Surveys | 1 | 2013 | 95 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 2777 | 0.030 |
Why?
|
| Unsafe Sex | 1 | 2012 | 20 | 0.030 |
Why?
|
| Community Health Workers | 1 | 2013 | 62 | 0.030 |
Why?
|
| Lymphocyte Count | 2 | 2006 | 114 | 0.030 |
Why?
|
| Caregivers | 1 | 2017 | 561 | 0.020 |
Why?
|
| Sibling Relations | 1 | 2011 | 13 | 0.020 |
Why?
|
| Quality of Life | 2 | 2011 | 1913 | 0.020 |
Why?
|
| Educational Status | 1 | 2011 | 267 | 0.020 |
Why?
|
| Diarrhea, Infantile | 1 | 2010 | 38 | 0.020 |
Why?
|
| Dehydration | 1 | 2010 | 37 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 659 | 0.020 |
Why?
|
| Virus Shedding | 1 | 2010 | 79 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2011 | 394 | 0.020 |
Why?
|
| Phenotype | 1 | 2019 | 4151 | 0.020 |
Why?
|
| Mental Processes | 1 | 2009 | 41 | 0.020 |
Why?
|
| Immunoglobulin A | 1 | 2009 | 195 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2013 | 1362 | 0.020 |
Why?
|
| Memory | 1 | 2012 | 357 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 5013 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2012 | 921 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2010 | 613 | 0.020 |
Why?
|
| Hospitals, Pediatric | 1 | 2013 | 776 | 0.020 |
Why?
|
| Sex Factors | 2 | 2006 | 1238 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2010 | 239 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2009 | 188 | 0.020 |
Why?
|
| Lipopeptides | 1 | 2007 | 33 | 0.020 |
Why?
|
| Sacrum | 1 | 2007 | 29 | 0.020 |
Why?
|
| Voriconazole | 1 | 2007 | 35 | 0.020 |
Why?
|
| Perinatal Care | 1 | 2008 | 68 | 0.020 |
Why?
|
| HMGB1 Protein | 1 | 2007 | 33 | 0.020 |
Why?
|
| Peptides, Cyclic | 1 | 2007 | 53 | 0.020 |
Why?
|
| Echinocandins | 1 | 2007 | 44 | 0.020 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2008 | 223 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 3626 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 1296 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 1008 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2009 | 758 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2008 | 872 | 0.020 |
Why?
|
| Feces | 1 | 2010 | 699 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2006 | 38 | 0.020 |
Why?
|
| Graft Survival | 1 | 2008 | 522 | 0.020 |
Why?
|
| Triazoles | 1 | 2007 | 138 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2013 | 15853 | 0.020 |
Why?
|
| Graft Rejection | 1 | 2008 | 576 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2006 | 755 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2007 | 292 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 2008 | 592 | 0.010 |
Why?
|
| Texas | 1 | 2013 | 3528 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2007 | 375 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2010 | 1750 | 0.010 |
Why?
|
| Survival Rate | 1 | 2008 | 1997 | 0.010 |
Why?
|
| NADPH Oxidases | 1 | 2004 | 115 | 0.010 |
Why?
|
| Comorbidity | 1 | 2008 | 1490 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 1407 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 2002 | 139 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2004 | 400 | 0.010 |
Why?
|
| Th1 Cells | 1 | 2002 | 147 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 2002 | 237 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2002 | 181 | 0.010 |
Why?
|
| Smoking | 1 | 2006 | 1028 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2008 | 3229 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 1468 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2004 | 1871 | 0.010 |
Why?
|
| Respiratory Hypersensitivity | 1 | 1997 | 51 | 0.010 |
Why?
|
| Eosinophilia | 1 | 1997 | 102 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2004 | 2030 | 0.010 |
Why?
|
| Hypersensitivity | 1 | 1997 | 178 | 0.010 |
Why?
|
| Itraconazole | 1 | 1994 | 25 | 0.010 |
Why?
|
| Granulocytes | 1 | 1994 | 65 | 0.010 |
Why?
|
| Survivors | 1 | 1995 | 345 | 0.010 |
Why?
|
| Middle Aged | 1 | 2004 | 25639 | 0.000 |
Why?
|